Toyota City, Japan, Nov 29, 2024 - (JCN Newswire via SeaPRwire.com) - TOYOTA GAZOO Racing (TGR) announced today a partially upgraded model of the Supra (3.0-liter) and the special-edition Supra "A90 Final Edition". The special-edition model is slated for global release with a limited run of 300 units. The planned regions for introduction and scheduled sales-launch timing are described below.Supra (3.0-liter) Partially upgraded modelGradual global introduction, including in Japan, Europe, and Australia, etc.Sequentially from spring 2025Special-edition modelSupra "A90 Final Edition"JapanEuropeJapan: Under considerationEurope: In spring 2025Ever since its first generation*1 in 1978, the Toyota Supra has earned legions of fans with its faithfully retained front-engine, rear-wheel-drive layout powered by an in-line six-cylinder engine*2. Also, in addition to the Supra having competed in the Super GT and numerous other types of motorsports events, the Supra-based, race-specific GR Supra GT4 has enabled customers to enjoy driving in various races around the world.In 2019, driven by the strong desire of Chairman Akio Toyoda, aka Master Driver Morizo, the Supra stormed back after a 17-year absence. Said Chairman Toyoda upon its release: "Back in the day, I spent countless hours driving an old Supra at Nürburgring to become a master driver. Supra is like an old friend that holds a special place in my heart. While other manufacturers were putting their beautiful new prototypes which they were going to introduce through the paces, I was driving an old Supra that was no longer in production. So even though Toyota had no plans to make a new Supra, just like a lot of other die-hard Supra fans around the world, I secretly wanted to make it happen. The new GR Supra was born through testing at Nürburgring, and I can honestly say that it is a car that is fun to drive and better than ever." The current Supra has continued to evolve since its launch, with partially upgraded models released in 2020 and 2022.The latest partially upgraded Supra aims to deliver a more integrated driving experience for unrestrained driving joy not only on city streets but also on winding roads and circuits. It features improved braking performance for safety and security, an increased-rigidity body, suspension, and chassis, optimized tuning, and enhanced aerodynamic performance.Additionally, to express its gratitude to current-model Supra fans around the world for their patronage, and for the model being favored by numerous teams in various motorsports such as GT racing, drift competitions, and NASCAR, TGR has created the limited special-edition Supra "A90 Final Edition" as the current model's culmination. This special-edition Supra boasts numerous upgraded driving-related elements, such as increased engine output and torque, strengthened brakes and body rigidity, and a KW suspension system, with such systems being a racing car favorite, and the use of high-grip tires. The result is a special, ultimate high-performance, high-spec model that has been optimally tuned in sync with the Supra's natural evolution.Although the production of the current Supra is scheduled to end with the Supra "A90 Final Edition" as the model's culmination, TGR will continue to hone the Supra through motorsports activities going forward.(1) Debuted in 1978 in North America as the Celica Supra and in Japan as the Celica XX; the Japanese-market first-generation Supra (launched in 1986) was the third-generation Supra elsewhere.(2) The current Supra is also available with an in-line four-cylinder engine.(3) Alcantara® is a registered trademark of Alcantara S.p.A.For more information, visit https://global.toyota/en/newsroom/toyota/41894560.html.About Toyota Toyota strives to be a strong corporate citizen, engaging with and earning the trust of its stakeholders, and to contribute to the creation of a prosperous society through all its business operations.Our corporate principles form the basis of our initiatives, reflect values that enable action, and drive our mindset.For the latest Toyota-related news and information:https://tinyurl.com/ToyotaPressReleasenewsroom@global.toyota Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Nov 28, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd (MHI) successfully achieved the key milestone of 1,200 hours of operation in a long-term durability test of its 90 MPa (900 bar) Class Ultra-High-Pressure Liquid Hydrogen Booster Pump.(1) Liquid hydrogen pumps are used at hydrogen refueling stations to refuel hydrogen fuel cell vehicles and hydrogen tube trailers.During the test, the pump completed 1,500 refueling cycles without downtime or replacement of major parts used at the cryogenic temperatures. This validates MHI's best-in-class operational reliability in hydrogen refueling allowing for dependable high flow rates of 160 kg per hour at a discharge pressure of 90 MPa (900 bar). The results of this long-term durability test demonstrate significant progress on the path to a future hydrogen economy.This test was conducted with FirstElement Fuel, Inc. (FEF), world-leader in hydrogen refueling solutions, at the Livermore Hydrogen Hub under hydrogen refueling station conditions.(Note2)The test started in April 2023 and was completed in November 2024. During this test, the pump- completed 1,500 refueling cycles at cryogenic temperatures of approximately -253°C (-423°F)- achieved 1,200 hours of operations without downtime and without replacement of major parts- pumped approximately 140 tons of liquid hydrogen (the equivalent of refueling5,000 fuel cell buses)(Note3), and- generated negligible boil-off gas during pump operation.The test was an overwhelming success and proved that this pump will make positive contributions to the reliability and efficiency of hydrogen refueling stations.The pump will be installed at a large-scale hydrogen station dedicated to clean commercial mobility in Japan and is scheduled to go into commercial operation in April 2025 simultaneously with the opening of the station.MHI will continue to provide best-in-class solutions to reduce the carbon footprint around the world. Our Ultra-High-Pressure Liquid Hydrogen Booster Pump is currently being introduced to the global market. This and new advanced solutions will continue to add value on society's path to a future hydrogen economy.(1) With an energy consumption just 25% that of hydrogen gas booster pumps, liquid hydrogen booster pumps offer an environmentally-friendly alternative for a hydrogen-oriented society. The advanced technology used in the MHI Ultra-High-Pressure Liquid Hydrogen Booster Pump was made possible by our cryogenic technology cultivated through research programs into liquid oxygen and liquid hydrogen engines for rockets, as well as technology and experience cultivated through the delivery of various industrial pumps, including those for nuclear power plants. For details, please refer to the following URLs: www.mhi.com/news/210406.htmlhttps://www.mhi.com/news/23091101.html(2) MHI believes in conducting full scale tests using liquid hydrogen under actual operating conditions;therefore, the demonstration tests were conducted at FEF's Hydrogen Hub in Livermore, California.3Assuming that one hydrogen fuel cell bus requires 28 kg to refuel.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Nov 28, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD dementia (early AD).LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques in AD, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.It is estimated there were approximately 900,000 dementia patients in South Korea in 2021,1 with one in ten people over the age of 65 suffering from dementia,1 and one in five from mild cognitive impairment (MCI).2 It is reported that Alzheimer’s dementia patients account for about 70% of all dementia patients.2 The average annual nursing care/medical costs per dementia patient is estimated to be 21.1 million South Korean Won (KRW), while the cost for patients with severe dementia reaches 33.1 million KRW.1Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In South Korea, Eisai Korea Inc. will distribute the product and conduct information provision activities.Eisai Korea Inc. has been a pioneer in the field of dementia for many years, focusing on activities such as raising disease awareness. In recent years, Eisai Korea Inc. has been working with various stakeholders, including healthcare professionals, academic societies, patient groups, care centers, health checkup companies, and diagnostic companies, to create a dementia ecosystem that promotes AD awareness and early diagnosis/treatment. Eisai Korea Inc. will first launch this drug in the private market, including the establishment of a Patient Assistance Program, to deliver lecanemab to patients awaiting the treatment, aiming to make an impact not only on patients but also on their caregiving families and South Korean society.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.3 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.4About LecanemabLecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates and Great Britain for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). The treatment’s approvals in these countries was based on Phase 3 data from Eisai’s global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.Lecanemab is marketed in the U.S., Japan, China, Great Britain and others, and is under regulatory review in 17 countries and regions, including the European Union. In November 2024, the treatment received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody back-up was signed in May 2015.About Eisai Co., Ltd. Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube. Biogen Safe Harbor This news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements. References (1) Korean dementia observatory 2022: National Institute of Dementia (Korean) (2) Korean dementia observatory 2021: National Institute of Dementia (Korean) (3) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z (4) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Inc. (U.S.)Julie Edelman+1 201-753-1945INVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department TEL: +81 (0)70-8688-9685Biogen Inc.Jack Cox+1 781-464-3260public.affairs@biogen.com Biogen Inc.Stephen Amato+1 781-464-2442IR@biogen.com Copyright 2024 JCN Newswire via SeaPRwire.com.